IPC 2025
Athens, Greece, 24 - 26 Jun 2025
We are looking forward to supporting the 18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health in June 2025. Whilst at the event Dr Elizabeth Crone, Head of Business Development, Research Products and Services Europe will be presenting the below talk:
‘Breath-taking analysis of microbial metabolites.’
This three-day event will provide the opportunity to explore the latest advancements in probiotics, prebiotics, and gut microbiota with leading scientists, researchers, and industry experts. IPC2025 will showcase cutting-edge research, clinical insights, and emerging trends shaping the future of microbiome science.
We’re excited to attend, connect with key innovators, and engage in discussions that will drive progress in this rapidly evolving field.
If you are interested in learning more about the work Owlstone Medical is doing, please get in touch to meet with us at the conference.
Meet the Team:
Dr Elizabeth Crone
Liz who is Head of Business Development, Research Products and Services Europe, will be attending the event. She has a strong technical background, with a biochemistry degree from Leeds University and a PhD from the University of Cambridge in biophysical chemistry, as well as several years consulting experience on technical innovation projects for companies like J&J, P&G and Shell. For the last decade, she has focussed on her passion: helping companies with potentially life-changing innovative technologies bring them to where they can be most useful. Liz now works in Owlstone, liaising with European-based companies and leading academics to help them explore and utilize breath as a biomarker matrix to advance their research.
Dr Ben Constant
Dr Ben Constant is a Business Development Executive at Owlstone Medical, where he is dedicated to advancing breath biomarker research.
Ben completed his undergraduate studies in Biomedical Sciences at the University of Sheffield, before pursuing a PhD at the University of Cambridge under the supervision of Dr Wei Li in the Department of Medicine. His doctoral research focused on elucidating the mechanisms of action of a novel pharmaceutical treatment for obesity.
Ben has a diverse background in the medical technology sector. He previously worked at Ortho Clinical Diagnostics, where he contributed to the development of a diagnostic test for heart attacks. Additionally, he has served as a technical consultant, assisting MedTech innovators in bringing their cutting-edge technologies to market.
In his current role, Ben is passionate about collaborating with leading scientists across Europe and Asia, helping them explore how breath biomarkers can enhance their research and clinical outcomes.
